Concepedia

Histone methyltransferase SMYD2 selective inhibitor LLY-507 in combination with poly ADP ribose polymerase inhibitor has therapeutic potential against high-grade serous ovarian carcinomas

Asako Kukita, Kenbun Sone, Katsutoshi Oda, Ryuji Hamamoto, Syuzo Kaneko, Masaaki Komatsu, Miku Wada, Harunori Honjoh, Yoshiko Kawata, Machiko Kojima,

Biochemical and Biophysical Research Communications · 2019 · 33 citations · 20 references

DOI

Concepts

References

20

The language of covalent histone modifications

Brian D. Strahl, C. David Allis · Nature · 2000 · 8.6K citations

, , +12

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

, , +17

Repression of p53 activity by Smyd2-mediated methylation

Jing Huang, Laura Perez-Burgos, Brandon J. Placek et al. · Nature · 2006 · 620 citations

, , +14

Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex

Mark A. Brown, Robert J. Sims, Paul Gottlieb et al. · Molecular Cancer · 2006 · 312 citations · Full text

, , +8

Ovarian Cancer Pathogenesis: A Model in Evolution

Alison M. Karst, Ronny Drapkin · Journal of Oncology · 2009 · 294 citations · Full text

, , +12